Prevention of sudden cardiac death.
Although the annual incidence of sudden cardiac death (SCD) is dropping in the United States, therapies for the patient who has survived a SCD episode or is at high risk of developing SCD in the future are now well established. The implantable cardioverter defibrillator (ICD) has emerged from a series of well done randomized clinical trials of the 1990s as providing a survival benefit in carefully defined patient groups with low ejection fraction of any cause. Patients with either an ischemic or idiopathic dilated cardiomyopathy and an EF <or=35% show a significant survival benefit with the ICD and maximal medical therapy. Many challenging patients (e.g., those with long QT syndrome or Brugada syndrome) who have a reasonably high incidence of sudden death have not been the subject of clinical trials involving the ICD and therapy depends on risk stratification that is currently not completely agreed upon. An exciting research frontier of the future will be those that attempt to integrate the appropriate role of the ICD with the ability of chronic resynchronization therapy to enhance left ventricular function in the damaged ventricle.
Cannom
David S
DS
Good Samaritan Hospital, Los Angeles, California 90017, USA. dcannom@lacard.com
D002311:Cardiomyopathy, Dilated / Q000401:mortality* / Q000628:therapy*; D015897:Comorbidity; D003324:Coronary Artery Disease / Q000401:mortality* / Q000628:therapy*; D016757:Death, Sudden, Cardiac / Q000453:epidemiology* / Q000517:prevention & control*; D004554:Electric Countershock / Q000379:methods / Q000706:statistics & numerical data*; D006801:Humans; D015994:Incidence; D010818:Practice Patterns, Physicians'; D015995:Prevalence; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome